Market's view on Crystal Amber
Published on April 2024
- The obesity rate in England has risen significantly from 14.9% in 1993 to 28% in recent years, indicating a growing health issue.
- Morphic Medical’s EndoBarrier is awaiting approval in the US and is hoping for CE mark approval in the UK and Europe, potentially providing a non-surgical weight loss solution for severely obese patients.
- The EndoBarrier could be a significant aid in long-term weight management without the need for medication or major surgery.
- Recent attention was drawn to Morphic by a Bernstein tweet linking to a Daily Mail article about the EndoBarrier.
- Discussions are ongoing about the potential financial implications of Crystal Amber Asset Management’s sale of a significant number of shares.
- The financial operations include share repurchases authorized up to 15% of capital, with significant funds still available for further repurchasing.
- Concerns were raised about the need to include discounted future revenue streams in net asset values (NAVs), specifically related to potential profits from the Prax project.
- The share price has been influenced by temporary buybacks, suggesting a strategy to manage share price fluctuations.
- Crystal Amber’s net asset value (NAV) showed improvement, possibly affected by an improvement in DLAR share price.
- Queries were made regarding whether the Crystal Amber Fund’s NAV includes expected payments from PRAX, indicating a focus on detailed financial assessments.
- Speculation about potential impacts of corporate actions on share prices, including dividends and share buybacks, reflects a strategic approach to investment decisions.